Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH

Stopped Strategic re-prioritization by the IMP supplier. Decision not safety-related

Conditions

• Primary Pulmonary Arterial Hypertension
• Chronic Thromboembolic Pulmonary Hypertension

Interventions

• DRUG: Riociguat

Sponsor

Heidelberg University

Collaborators

• [object Object]